ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

ANALYSIS OF LIPID PEROXIDATION STATUS IN PROSTATE CANCER PATIENTS RECEIVING RADIOTHERAPY IN PAKISTAN

AUTHORS:

Zainab Ejaz, Shoaib Jamil, Muhammad Faisal Shahzad

ABSTRACT:

Introduction: Prostate cancer is the fourth most common male malignancy worldwide and is the commonest malignancy of older age. The prevalence of prostate cancer increases with rise in age. It is the major cause of morbidity and mortality in male older than 65 years of age worldwide. Objectives: This study is aim to analyze the lipid peroxidation status in prostate cancer patients who are receiving radiotherapy in Pakistani hospitals. Methodology of the study: This descriptive study was conducted in Sheikh Zaid Hospital Rahim Yar Khan during January 2019 to July 2019. Those prostate cancer patients who receiving radiotherapy were selected to study the lipid peroxidation status in the diseased condition. Results: The data pertaining in the table explained that radiotherapy and chemotherapy both effect on the MDA levels of cancer patients. The statistical analysis shows that levels of MDA become increasing in prostate cancer patients who received adjuvant radiotherapy or simple radiotherapy. The level of MDA before radiotherapy is 3.48±0.65and it become increases in post radiotherapy. As the value of MDA post radiotherapy is 5.66±0.95. But in case of adjuvant radiotherapy it becomes 3.27±0.16 (pre-treatment) and 6.79±0.40 (post-treatment). The levels of MDA become increased because cell membrane is damaged due to therapies. Conclusion: It is concluded that MDA is one of the important marker of body for protecting the body against the diverse effects of radiotherapy. Although many anti-neoplastic agents have clearly established mechanisms of action that are not dependent upon the generation of ROS/RNS, these drugs can only mediate their anticancer effects on cancer cells that are exhibiting unrestricted progression through the cell cycle.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.